Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
about
The pathobiology of vascular dementiaMultivariate classification of blood oxygen level-dependent FMRI data with diagnostic intention: a clinical perspectiveHypothalamic-pituitary-gonadal axis involvement in learning and memory and Alzheimer's disease: more than "just" estrogenAn over expression APP model for anti-Alzheimer disease drug screening created by zinc finger nuclease technologyA Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling.Advancing biomarker research: utilizing 'Big Data' approaches for the characterization and prevention of bipolar disorder.Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.The future of blood-based biomarkers for Alzheimer's disease.Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's diseaseAn enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function.Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer's diseaseClinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's diseaseThe Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target PopulationsLuteinizing hormone: Evidence for direct action in the CNSEarly detection of cryptic memory and glucose uptake deficits in pre-pathological APP miceHave we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?Metabolic profiling of Alzheimer's disease brainsCentral nervous system biomarkers for antiobesity drug developmentPRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome.Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders,Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.Biomarkers in Sporadic and Familial Alzheimer's Disease.Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease.Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease.Intellectual Disability, Mild Cognitive Impairment, and Risk for Dementia.No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease.18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports.Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.Aptamers as biomarkers for neurological disorders. Proof of concept in transgenic mice.Evolving Relevance of Neuroproteomics in Alzheimer's Disease.
P2860
Q27006033-3F076E88-79E4-43DE-B9E2-F9377A3E8EF2Q27026903-EF61EF9A-D326-435A-AB94-116598419448Q27027598-4DE5CB2D-EA43-406B-907D-088CC3C8BAE1Q28534870-327A3A78-2A87-43D8-A471-C56372B933F9Q30235315-67C37EA9-B3FA-4A4E-A49F-6C2EFD464E3AQ30713152-41D0D575-9B6A-4369-A15C-7D489A65CC58Q30996727-2F5D57CC-E1FF-4215-8548-2644A1356A22Q30996799-307CECD1-3E80-4F94-A886-C4E880318085Q34026317-8F13132C-FD6E-4679-98AA-FDC66A9FC1D8Q34129473-4DAEB259-4CDC-4EF5-96A6-0237582DF90CQ34746609-7C6C5241-A1EF-43CC-815A-6193335D4F19Q34987497-011CF6B9-B9A7-4594-8F32-73EF52B4066AQ35284971-BC16C709-FDE7-4487-853E-5715610D93B4Q36165011-42BD1DB9-206B-4971-94DA-F08EB2CC525CQ36543895-D65E6FBF-524D-4489-985B-12A75D44FE19Q36974723-DC3D35A0-D293-4F86-91F5-8ABDCA503FA0Q36998387-67E1AE72-D50F-4C73-83DF-D3271D306460Q37072582-42460F50-3891-4BFC-A8CF-E468B1C80142Q37382285-1A5D5D3D-3F6C-4C4A-A7E7-3BB7AB3030B8Q37718557-37BB05C6-A1F5-4B07-ACB7-CEDED0F1F5A9Q37741452-A08F6FFB-528C-4559-BF5B-41FAD419682CQ38060658-32A8CF86-23F0-4ABE-9EB2-940088D577ACQ38127470-5A50E6AD-7E6B-46D7-9D24-8BCAD27C7002Q38210117-CC2F40C5-97CF-4001-90DE-B89A03500F5CQ38243166-E21E4111-87F4-42BA-87FE-08BA33C78819Q38299414-A756D95A-7AB2-4646-9A9F-6D1035730350Q38344088-C2088AAD-8A68-4D1B-90AD-BD8CEFCCE78DQ38592041-F317A746-140E-4E7E-BE22-B438ABD23EC5Q38873321-15711EC2-8ADA-4CFC-AD14-3752E1959524Q38915171-3AF59548-ECF8-44B7-8197-BF09C959221AQ39419112-9DE500DF-4E5B-4E84-BEBA-4163BEB7153BQ42876186-D55CABF6-0A40-49D3-8953-45380180A7C6Q46631793-73AD6834-92A2-44F5-A494-668B483F457AQ47209544-58B98E52-7613-404C-8C89-C1090105064CQ47209556-98BF67B0-8F30-40A9-9AA7-E73A250D352DQ47587631-850BFB65-24B2-4CB3-B2A3-C04047ECF856Q47701456-BE642108-1DC9-4F86-90E1-9E45E412C321Q47761998-0D7E515F-7109-49B3-8CD2-BE70A424E0CFQ48303030-355038E5-D694-40B2-9A67-ED95F5CC427DQ50999408-31CC1C80-7CEF-45CD-8447-B0817A070D27
P2860
Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Development of biomarkers to c ...... the therapeutic Gordian Knot.
@en
type
label
Development of biomarkers to c ...... the therapeutic Gordian Knot.
@en
prefLabel
Development of biomarkers to c ...... the therapeutic Gordian Knot.
@en
P1476
Development of biomarkers to c ...... the therapeutic Gordian Knot.
@en
P2093
Simone Lista
P304
P356
10.1016/J.JALZ.2012.05.2116
P577
2012-07-01T00:00:00Z